• Users Online:237
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 7  |  Issue : 3  |  Page : 109-115

A multi-centric double-blind homoeopathic pathogenetic trial of Cyclosporin

1 Regional Research Institute (H), Puri, Odisha, India
2 S-4, Central Research Institute (H), Noida, India
3 Central Council for Research in Homoeopathy, New Delhi, India

Correspondence Address:
Sujata Kumari Choudhury
Senior Research Fellow, Regional Research Institute(H), Puri
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-7168.119114

Rights and Permissions

Objective : To elicit the pathogenetic response of the drug Cyclosporin in homoeopathic potencies on apparently healthy human beings. Material and Methods : The drug Cyclosporin was proved by the Central Council for Research in Homoeopathy through double-blind placebo-controlled trial. The study was conducted in two centres. The drug was proved in two potencies (6C and 30C) on 50 apparently healthy volunteers who were selected after conducting pre-trial medical examinations by the medical specialists and routine laboratory investigations. In the first phase the volunteers were given 56 doses (4 doses per day for 14 days) of placebo. In the next two phases, 56 doses (4 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the proving masters. The data obtained from the two centers were compiled at proving-cum-data processing cell at Central Council for Research in Homoeopathy (CCRH) headquarters after decoding. Results : Out of 50 provers, 33 were on actual drug trial and 17 were on placebo. Eleven provers manifested symptoms. The drug was able to produce symptoms in each potency in most parts of the body. Conclusion : The pathogenetic responses elicited during the proving trial expands the scope of use of the drug Cyclosporin and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded426    
    Comments [Add]    

Recommend this journal